Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AtriCureATRC +4.78%78 EV-to-OCF is 30.93 as of Aug. 08, 2026. GuruFocus rates ATRC with a GF Score™ of 78/100 and a GF Value™ of $39.38 (Fairly Valued). The stock has 5 warning signs investors should review. Among 852 Medical Devices & Instruments companies, AtriCure ranks worse than 83.1% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, AtriCure's Enterprise Value is $2,008.6 Mil.
AtriCure's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $64.9 Mil. Therefore, AtriCure's EV-to-OCF for today is 30.93.
The historical rank and industry rank for AtriCure's EV-to-OCF or its related term are showing as below:
ATRC'
s EV-to-OCF Range Over the Past 10 Years
Min: -1358.63 Med: -82.79 Max: 3788.67
Current: 30.93
During the past 13 years, the highest EV-to-OCF of AtriCure was 3788.67. The lowest was -1358.63. And the median was -82.79.
ATRC's EV-to-OCF is ranked worse than 83.1% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.835
vs ATRC: 30.93
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AtriCure's share price for today is $41.39.
AtriCure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AtriCure EV-to-OCF Related Terms
AtriCure EV-to-OCF Historical Data
* Premium members only.
The historical data trend for AtriCure's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, AtriCure's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AtriCure EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where AtriCure's EV-to-OCF falls into.
AtriCure's current Enterprise Value is $2,008.6 Mil.
AtriCure's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $64.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtriCure (ATRC) has a EV-to-OCF of 30.93 as of Aug. 08, 2026. According to the industry distribution chart, AtriCure ranks #708 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 83.1%.
Is AtriCure's EV-to-OCF too high?
AtriCure's current EV-to-OCF is 30.93. The Medical Devices & Instruments industry median EV-to-OCF is 7.84. AtriCure's value of 30.93 is 294.8% above this industry median. Based on the distribution chart, AtriCure ranks #708 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AtriCure has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's EV-to-OCF compare to BLFS and PLSE?
According to the Medical Devices & Instruments industry distribution chart, AtriCure ranks #708 out of 852 companies for EV-to-OCF. This places AtriCure in the lower half of its industry. The industry median EV-to-OCF is 7.84. AtriCure's value of 30.93 is 294.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.84, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtriCure's current EV-to-OCF of 30.93 is 294.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtriCure's current EV-to-OCF is 30.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Fairly Valued. The stock's GF Value™ is $39.38, compared to a current price of $41.39 — trading 5.1% above its estimated fair value. The current EV-to-OCF is 30.93 and 294.8% above the Medical Devices & Instruments industry median of 7.84. AtriCure's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For AtriCure (ATRC), the current EV-to-OCF is 30.93 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AtriCure (ATRC) Overvalued in 2026?
Based on GuruFocus' analysis, AtriCure stock appears to be overvalued.
The current stock price of $41.39 is trading 5.1% above its estimated GF Value™ of $39.38.
GuruFocus considers AtriCure to be Fairly Valued.
Key valuation signals for ATRC:
EV-to-OCF: 30.93
GF Value™: $39.38 vs. price of $41.39 (5.1% above fair value)
Industry Position: 294.8% above the Medical Devices & Instruments median (#708 of 852)
No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
78GF Score
Get the complete analysis for ATRC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRC has been successfully added to your 
